REAL and CALM: What have we learned?

Movement Disorders

Volumn 18, Issue 7, 2003, Pages 839-840

  Morrish, P K ^a  

^a PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

CLINICAL EXAMINATION; CLINICAL TRIAL; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; DOPAMINERGIC SYSTEM; HUMAN; INTERMETHOD COMPARISON; LETTER; NERVE CELL DEGENERATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RELIABILITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION PROCESS;

ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CLINICAL TRIALS; CORPUS STRIATUM; DISEASE PROGRESSION; DOPAMINE; FEASIBILITY STUDIES; HUMANS; INDOLES; LEVODOPA; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PUTAMEN; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; THIAZOLES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0042591609     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10448     Document Type: Letter

References (15)

1. Morrish PK. Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord 2002;17:229-232.
2. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, Weiner W, Welsh M. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
3. Whone AL, Rakshi JS, Watts RL, Brooks DJ. Two trials demonstrating disease-slowing effects of ropinirole, compared with L-dopa, in early Parkinson's disease. Mov Disord 2002;17(Suppl. 5):85-86.
4. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
5. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
6. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36: 759-764.
7. 18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996;119: 2097-2103.
8. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
9. Marek K, Seibyl J, Mcdermott M, Fahn S, Lang A, Ahlskog JE, Maraganore DM, Uitti RJ, Uhl GR, Morrish PK. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. JAMA 2002;288:312-313.
10. Olanow CW, Hauser RA, Gauger L, Malpira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D and Esterlitz J. The effect of deprenyl and Levodopa on ythe progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
11. Shults J, Effects of coenzyme Q10 in early Parkinson's disease, evidence for slowing of the functional decline (the QE2 study). Mov Disord 2002;17(Suppl. 5):S14.
12. Morrish PK, Sawle GV, Brooks DJ Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
13. Fahn S. Results of the ELLDOPA (earlier vs. later levodopa) study. Mov Disord 2002;17(Suppl. 5):S13.
14. 123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
15. 18F]dopa-PET study. Brain 1999;122:1637-1650.